Thermo Fisher Scientific (NYSE:TMO) Upgraded to Strong-Buy at Wolfe Research

Wolfe Research upgraded shares of Thermo Fisher Scientific (NYSE:TMO) to a strong-buy rating in a research note issued to investors on Monday,Zacks.com reports.

TMO has been the topic of several other reports. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Barclays lowered their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Stifel Nicolaus lowered their price target on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Finally, DZ Bank started coverage on Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Buy” and an average price target of $612.24.

Thermo Fisher Scientific Stock Down 2.7%

TMO opened at $480.62 on Monday. Thermo Fisher Scientific has a 12 month low of $385.46 and a 12 month high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The stock has a market cap of $178.61 billion, a P/E ratio of 26.42, a P/E/G ratio of 2.19 and a beta of 0.88. The stock’s 50 day moving average price is $480.40 and its 200 day moving average price is $533.68.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same period last year, the firm earned $5.15 EPS. The firm’s revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts predict that Thermo Fisher Scientific will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Hedge funds have recently modified their holdings of the stock. Legacy Wealth Managment LLC ID boosted its position in shares of Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares during the period. High Note Wealth LLC boosted its position in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after buying an additional 29 shares during the period. Swiss RE Ltd. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $28,000. JPL Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the third quarter worth $28,000. Finally, Beacon Financial Strategies CORP acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $29,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.